(Benzoyl peroxide + tretinoin) is under clinical development by Ortho Dermatologics and currently in Phase III for Acne Vulgaris. According to GlobalData, Phase III drugs for Acne Vulgaris have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Benzoyl peroxide + tretinoin)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Benzoyl peroxide + tretinoin) overview

IDP-120(A fixed dose combination of benzoyl peroxide and tretinoin) is under development for the treatment of acne vulgaris. It is administered topically as a gel .Benzoyl peroxide is a powerful antimicrobial agent and tretinoin is a naturally occurring retinoic acid that acts by targeting the retinoic acid receptors (RARs).

Ortho Dermatologics overview

Ortho Dermatologics, a subsidiary of Bausch Health Companies Inc, engaged in research and development of dermatology solutions, therapeutics for the treatment of actinic keratosis, psoriasis, acne and other skin diseases. The company is headquartered in Somerset, New Jersey, the US.

For a complete picture of (Benzoyl peroxide + tretinoin)’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.